SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

The company says preclinical trials demonstrate its signature molecule can help prevent cell damage that can lead to ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe ...

Sitala Bio Ltd. has prepared new indole derivatives acting as complement factor B (CFB) inhibitors. They are thus reported to be useful for the treatment of age-related macular degeneration, ...

WALTHAM, Mass. - Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.7 billion market cap biotech company showing impressive revenue growth of 162% over the last twelve months, today announced that the ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

Naples, Italy-based rare diseases focused biotech BIOVIIIx says that its subsidiary Anbition and Japanese firm TagCyx ...